lactose has been researched along with paclitaxel in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Ding, F; Jiang, G; Qiu, T; Wang, Y | 1 |
Choi, HG; Jin, SG; Kim, DS; Kim, DW; Kim, JC; Kim, JO; Kim, KS; Kim, YI; Park, JH; Woo, JS; Yong, CS; Youn, YS | 1 |
5 other study(ies) available for lactose and paclitaxel
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preparation and evaluation of paclitaxel-loaded nanoparticle incorporated with galactose-carrying polymer for hepatocyte targeted delivery.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; Drug Compounding; Drug Delivery Systems; Emulsifying Agents; Endocytosis; Galactose; Hep G2 Cells; Hepatocytes; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Lactose; Liver Neoplasms; Nanoparticles; Paclitaxel; Particle Size; Polystyrenes; Polyvinyl Alcohol; Solubility; Surface Properties | 2012 |
Effect of HM30181 mesylate salt-loaded microcapsules on the oral absorption of paclitaxel as a novel P-glycoprotein inhibitor.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; Benzopyrans; Biological Availability; Capsules; Drug Carriers; Isoquinolines; Lactose; Male; Mesylates; Methylcellulose; Paclitaxel; Phosphoric Acids; Polymers; Powders; Rats; Rats, Sprague-Dawley; Silicon Dioxide; Solubility; Tetrazoles | 2016 |